Nordic Nanovector ASA First Quarter 2016 Results: Strong Progress on All Priorities and Execution on Track

OSLO, Norway–(BUSINESS WIRE)–Nordic Nanovector ASA (OSE:NANO) announces its results for the first quarter 2016. A presentation of the results by the company’s senior management team will take place today at 8:30 a.m. CEST in Oslo – details below. Nordic Nanovector reports steady operational progress on Betalutin®’s clinical development plan in Follicular Lymphoma (FL), with recruitment of both sites and patients proceeding according to schedule. The Lymrit 37-01 study is on track to define th
Source: BusinessWire-Primary

Nordic Nanovector ASA First Quarter 2016 Results: Strong Progress on All Priorities and Execution on Track